divis
beat cent rais estim
adjust ep record vs last year cent figur sale
million model
adjust ep increas record vs
ep estim previous compani guidanc
aid new product tax rate vs improv margin
ep estim introduc estim
leader infect prevent equip report adjust ep vs
year earlier compar report year-over-year period yoy unless otherwis indic cent
figur adjust ep exclud purchas inventori step-up cost intang amort acquisition-
relat integr expens tax benefit due new tax law report net incom million
per share vs million per share
revenu increas million price bp million currenc benefit off-set
million divestitur constant currenc organ growth vs last quarter revenu
corpor total fell million revenu million
 revenu increas million
adjust gross profit rose million adjust gross margin increas bp
sale aid favor product mix price well bp improv divestitur partial
off-set bp fx headwind adjust sg expens million decreas
revenu vs expens million vs million equal revenu vs
adjust oper profit rose yoy million oper margin increas bp yoy
adjust tax rate around vs last year adjust net incom increas
million net margin rose sale vs adjust ep
pleas see import disclosur end report
healthcar product sale infect prevent procedur solut
healthcar provid world-wide includ capit equip washer steam ga steril surgic
tabl light clean chemistri relat mainten instal servic well consum
organ constant currenc basi million capit equip flat
backlog increas yoy million consum increas limit divestitur servic
increas approxim busi replac remain project
consum track procedur volum equip align building/rehab project
oper profit fell million group margin vs due increas spend
 fx headwind higher corpor cost
healthcar specialti servic rang specialti servic healthcar provid includ
hospit steril servic instrument scope repair linen manag due
linen divestitur divest synergi netherland linen busi sale rose
organ constant currenc basi due mainli strength instrument manag servic im
north america ad im busi europ oper profit jump
million vs million group margin vs higher volum without addit
growth invest product improv
appli steril technolog ast contract steril laboratori servic medic
devic manufactur pharmaceut custom other million sale rose
organ due increas volum segment core medic devic custom market share gain
group oper profit million group oper margin revenu vs
due revenu growth fx
life scienc ls consist capit equip consum product washer steril
etc equip mainten specialti servic pharmaceut manufactur research
institut lumpi busi due variabl construct deliveri schedul rose increas
organ million capit equip jump servic increas consum
flat ls backlog jump million new product includ hydrogen peroxid steril
well receiv ls longer lead time ls oper profit rose million
group margin slip vs consum highest margin follow servic
revenu essenti flat organ still record billion vs billion
million favor fx off-set divest busi consum and/or servic revenu equal
total ls grew organ ast grew servic revenu
adjust oper incom increas million margin bp yoy
tax rate vs adjust net incom million yoy net profit margin
rose bp sale adjust ep exclud special item rose record vs
year after-tax return averag equiti asset pre-tax invest capit
respect vs respect
balanc sheet march includ cash equival million major held
outsid unit state million repatri quarter equiti billion debt around
billion provid debt-to-tot capit ratio vs ebitda
pleas see import disclosur end report
divis wellington shield co llc
plc
flow oper cfo quarter million vs million year earlier total
million vs million net incom vs
debt reduc activ pursu acquisit primarili tuck-in share repurchas use
off-set option dilut compani rais dividend cent august quarterli rate
cent per share consecut annual increas
compani announc chairman john wareham stand re-elect juli
succeed current board member dr mohsen sohi compani appoint dr nirav shah
board vacanc mr shah becom senior scholar clinic excel research center
stanford univers later month previous serv commission state new
york
sale earn outlook
healthcar product benefit around new product launch plan primarili capit
equip addit consum launch ls benefit
growth segment backlog well new product start see benefit expand
outsourc model see improv im
compani could begin see benefit northwel partnership northwel hospit
group account surgic procedur new york deal give hub
long island provid central steril process northwel hospit partner
help drive addit outsourc activ compani anticip million revenu
project loss year due invest note earli sign potenti
outsourc opportun could see revenu around million includ northwel full-year run
rate futur year
june ep estim remain vs last year revenu million
ep estim vs record compani introduc guidanc
previou project revenu billion benefit favor fx
around million held back divestitur consum busi novemb
divestitur plan current target organ growth year
includ benefit price model oper margin record aid
divestitur remain cost synergi synergi around million continu improv
although expect pace indic tax rate
rang gross free cash flow estim per share respect assum
net incom million depreci amort million million exclud intang
amort around million alreadi deduct adjust net incom figur capit
spend million dividend million still project million free cash flow
ep estim introduc revenu billion oper incom
ep aid lower tax rate oper margin model bp
revenu long-term target mid-single-digit organ growth double-digit ep
share trade forward ep estim project
year growth rate rate hold due valuat remain posit fundament
includ satisfactori hospit spend benefit acquir synergi margin improv aid
pleas see import disclosur end report
divis wellington shield co llc
plc
recent divestitur sell ev-to-ebitda ratio project ebitda million
project ebitda million share trade price-to-earnings ratio base upon trail
report ep current
global hospit spend environ key variabl synergi deriv revenu
outsid subject compani increas geograph risk well vagari foreign currenc
fluctuat medic technolog compani product obsolesc and/or increas competit
relev risk regulatori issu continu import mani compani product process
subject fda approv and/or inspect
pleas see import disclosur end report
divis wellington shield co llc
plc -- earn model -- may
march fiscal year-end
mm ex per share
good sold
good sold
pleas see import disclosur end report
